http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2020, Vol. 29 ›› Issue (2): 90-101.DOI: 10.5246/jcps.2020.02.007

• Original articles • Previous Articles     Next Articles

Pharmacokinetics of different dosage of astragalus membranaceus of buyang huanwu decoction in rats with cerebral ischemic injury by microdialysis  combined with LC/MS

Shengxin Wang, Xiangli Yan, Haozhen Zheng, Jianye Yu, Aiming Yu, Xiao Shen, Lisheng Wang*   

  1. School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
  • Received:2019-10-12 Revised:2019-11-23 Online:2020-02-29 Published:2019-12-15
  • Contact: Tel.: +86-20-39358290, E-mail: wlis68@126.com
  • Supported by:
    National Natural Science Foundation of China (Grant No. 81373973, 81573872, 81873228) and Science and Technology Planning Project of Guangdong Province (Grant No. 2017KZDXM018).

Abstract:

To investigate the pharmacokinetics of effective components of Bu Yang Huang Wu Decoction (BYHWD) with different dosages of Astragalus (Yiqi groups and Huoxue groups ) applicating in rats with middle cerebral artery occlusion (MCAO). Replicating the animal model of cerebral ischemia-reperfusion in rats, establishing the liquid-mass spectrometry method for the determination of BYHWD and researching the pharmacokinetics of effective components of yiqi groups of BYHWD with different dosages of astragalus (3.09, 6.17, 12.34 g/Kg) and Huoxue goups (2.32 g/Kg) when applicated seperately in the rats suffering from cerebral ischemia reperfusion injury after femoral vein administration. The pharmacokinetics of formononetin and paeoniflorin in the different dosage groups of BYHWD met the one-compartment model, and the t1/2 of formononetin and paeoniflorin in the low-dose Yiqi and Huoxue groups were (88.43±3.82, 69.18±0.11) min,  MRT were (138.56±4.83, 113.62±2.42) min, and AUC0t were (28 488.35±4800.32, 140 614.80±23 954.05) ng/mL·min; The t1/2 of formononetin and paeoniflorin in the middle-dose Yiqi group and Huoxue group were (82.16±1.78, 67.08±3.69) min, and MRT were (127.95±2.70, 116.58±4.13), AUC0t were (48 619.25±6745.75, 159 026.00±15 003.33) ng/mL·min; The t1/2 of formononetin and paeoniflorin in the high-dose Yiqi and Huoxue groups were (80.29±1.12, 69.69±0.87) min, and MRT was (128.79±1.46, 118.78±4.56) min, AUC0t were (109 942.90±13 101.83, 189 417.90±22 311.00) ng/mL·min. The concentration rate of formononetin t1/2 brain was decreased with increase of Astragalus dose. However, no significant difference between these two variables was found during experiments. Furthermore, the experiments showed that the increasing dose of astragalus would affect the pharmacokinetic behavior of paeoniflorin in the Huoxue groups. More specifically, the result showed that paeoniflorin can be metabolized more slowly in the body when applicated in high dose of the jaundice administration groups . In this way, the effect of paeoniflorin can be lasted for longer time in the body and brain.

Key words: Bu Yang Huan Wu Tang, Pharmacokinetics, Microdialysis, Cerebral ischemia-reperfusion

CLC Number: 

Supporting: